CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: gemcitabine
Accession: CHEBI:175901
browse the term
Definition: A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.
Synonyms: related_synonym: 2',2'-Difluorodeoxycytidine; 2'-Deoxy-2',2'-difluorocytidine; 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; Formula=C9H11F2N3O4; InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1; InChIKey=SDUQYLNIPVEERB-QPPQHZFASA-N; SMILES=Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1; gemcitabina; gemcitabinum
alt_id: CHEBI:42752; CHEBI:5295
xref: Beilstein:5382060; CAS:95058-81-4; DrugBank:DB00441; Drug_Central:1283; KEGG:C07650; KEGG:D02368; LINCS:LSM-5333
xref_mesh: MESH:C056507
xref: PDBeChem:GEO; PMID:11034044; PMID:11061612; PMID:11088063; PMID:11122828; PMID:11132538; PMID:11142482; PMID:11221019; PMID:11356111; PMID:11374818; PMID:11489002; PMID:11504793; PMID:11510027; PMID:11585734; PMID:11595724; PMID:11807603; PMID:11859947; PMID:11901308; PMID:12057041; PMID:12057046; PMID:12057157; PMID:12115355; PMID:12142097; PMID:12520460; PMID:12571808; PMID:12722678; PMID:12722691; PMID:12743987; PMID:12761494; PMID:12798170; PMID:12917815; PMID:12954073; PMID:14606642; PMID:14653877; PMID:14720338; PMID:15131028; PMID:15160243; PMID:15221904; PMID:15282439; PMID:15297392; PMID:15542781; PMID:15637766; PMID:15744590; PMID:16001951; PMID:16041610; PMID:16080557; PMID:16143373; PMID:16149285; PMID:16317298; PMID:16500746; PMID:16555971; PMID:16584929; PMID:16807461; PMID:16807463; PMID:16894289; PMID:16905983; PMID:17101674; PMID:17296311; PMID:17296587; PMID:17347561; PMID:17429628; PMID:17460420; PMID:17602464; PMID:17639396; PMID:17887663; PMID:17939651; PMID:17941128; PMID:17987263; PMID:18035967; PMID:18050344; PMID:18086345; PMID:18166944; PMID:18186604; PMID:18257544; PMID:18348652; PMID:18773046; PMID:18789834; PMID:18819792; PMID:18981552; PMID:19034448; PMID:19177022; PMID:19399788; PMID:19839926; PMID:19879060; PMID:22763439; PMID:28594276; PMID:28608357; PMID:28912244; Patent:EP1939198; Patent:EP2108368; Patent:EP2275135; Patent:GB2136425; Patent:US2009124797; Patent:US2010111852; Patent:US4808614; Reaxys:5382060; Wikipedia:Gemcitabine
G
A2m
alpha-2-macroglobulin
increases expression
ISO
Gemcitabine results in increased expression of A2M protein
CTD
PMID:20531411
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
G
Abcb1a
ATP binding cassette subfamily B member 1A
decreases expression
ISO
Gemcitabine results in decreased expression of ABCB1 mRNA; Gemcitabine results in decreased expression of ABCB1 protein
CTD
PMID:35063459
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
G
Acp3
acid phosphatase 3
decreases expression
ISO
Gemcitabine results in decreased expression of ACP3 protein
CTD
PMID:20531411
NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
G
Adam17
ADAM metallopeptidase domain 17
multiple interactions
ISO
ADAM17 protein promotes the reaction [Gemcitabine results in increased cleavage of AREG protein]
CTD
PMID:20726858
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
G
Adipoq
adiponectin, C1Q and collagen domain containing
increases expression
ISO
Gemcitabine results in increased expression of ADIPOQ protein
CTD
PMID:20531411
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
G
Afp
alpha-fetoprotein
decreases expression
ISO
Gemcitabine results in decreased expression of AFP protein
CTD
PMID:20531411
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
G
Agpat2
1-acylglycerol-3-phosphate O-acyltransferase 2
decreases expression
ISO
Gemcitabine results in decreased expression of AGPAT2 mRNA
CTD
PMID:17039268
NCBI chr 3:9,416,842...9,428,567
Ensembl chr 3:9,416,843...9,428,371
G
Akt1
AKT serine/threonine kinase 1
affects response to substance multiple interactions
ISO
AKT1 protein affects the susceptibility to Gemcitabine [Gemcitabine co-treated with licoricidin] results in decreased phosphorylation of AKT1 protein; [licoricidin co-treated with Gemcitabine] results in decreased phosphorylation of AKT1 protein
CTD
PMID:15867245 PMID:29782821
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
G
Aldh1a1
aldehyde dehydrogenase 1 family, member A1
multiple interactions decreases expression
ISO
sulforaphane promotes the reaction [Gemcitabine results in decreased expression of ALDH1A1 protein]
CTD
PMID:20940707
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
G
Aldh1a3
aldehyde dehydrogenase 1 family, member A3
increases expression
ISO
Gemcitabine results in increased expression of ALDH1A3 mRNA
CTD
PMID:17039268
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
G
Aldh6a1
aldehyde dehydrogenase 6 family, member A1
increases expression
ISO
Gemcitabine results in increased expression of ALDH6A1 mRNA
CTD
PMID:17039268
NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656
G
Anapc1
anaphase promoting complex subunit 1
increases expression
ISO
Gemcitabine results in increased expression of ANAPC1 mRNA
CTD
PMID:17039268
NCBI chr 3:115,850,117...115,930,259
Ensembl chr 3:115,850,185...115,930,273
G
Ank3
ankyrin 3
increases expression
ISO
Gemcitabine results in increased expression of ANK3 mRNA
CTD
PMID:17039268
NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300
G
Ankrd1
ankyrin repeat domain 1
increases expression
ISO
Gemcitabine results in increased expression of ANKRD1 mRNA
CTD
PMID:17039268
NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919
G
Antxr1
ANTXR cell adhesion molecule 1
affects expression
ISO
Gemcitabine affects the expression of ANTXR1 mRNA
CTD
PMID:17039268
NCBI chr 4:119,590,770...119,778,232
Ensembl chr 4:119,590,771...119,778,232
G
Apcs
amyloid P component, serum
decreases expression
ISO
Gemcitabine results in decreased expression of APCS protein
CTD
PMID:20531411
NCBI chr13:85,373,338...85,374,134
Ensembl chr13:85,373,220...85,374,298
G
Apoh
apolipoprotein H
increases expression
ISO
Gemcitabine results in increased expression of APOH protein
CTD
PMID:20531411
NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329
G
Ar
androgen receptor
multiple interactions
ISO
Gemcitabine binds to and results in decreased activity of AR protein
CTD
PMID:25752796
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Areg
amphiregulin
multiple interactions increases expression increases cleavage decreases response to substance
ISO
ADAM17 protein promotes the reaction [Gemcitabine results in increased cleavage of AREG protein] Gemcitabine results in increased expression of AREG protein AREG protein results in decreased susceptibility to Gemcitabine
CTD
PMID:20726858
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
G
Arf1
ADP-ribosylation factor 1
decreases expression
ISO
Gemcitabine results in decreased expression of ARF1 mRNA
CTD
PMID:17039268
NCBI chr10:43,997,983...44,014,543
Ensembl chr10:43,997,986...44,014,434
G
Arnt
aryl hydrocarbon receptor nuclear translocator
increases expression
ISO
Gemcitabine results in increased expression of ARNT mRNA
CTD
PMID:20103597
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
G
Atf3
activating transcription factor 3
increases expression
ISO
Gemcitabine results in increased expression of ATF3 mRNA
CTD
PMID:17039268
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
G
Axin2
axin 2
affects expression
ISO
Gemcitabine affects the expression of AXIN2 mRNA
CTD
PMID:20103597
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
G
Axl
Axl receptor tyrosine kinase
multiple interactions
ISO
AXL protein promotes the reaction [Warfarin results in increased susceptibility to Gemcitabine]
CTD
PMID:26206560
NCBI chr 1:81,265,656...81,296,278
Ensembl chr 1:81,265,088...81,296,265
G
Bax
BCL2 associated X, apoptosis regulator
multiple interactions
ISO
[alvocidib co-treated with Gemcitabine] results in increased expression of BAX protein; [ICI 118551 co-treated with Gemcitabine] results in increased expression of BAX protein; [Mastic Resin co-treated with Gemcitabine] results in increased expression of BAX protein; [TNFSF10 co-treated with Gemcitabine] affects the localization of BAX protein
CTD
PMID:15770523 PMID:17671697 PMID:20523344 PMID:21570961
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
G
Bcl2
BCL2, apoptosis regulator
decreases expression multiple interactions
ISO
Gemcitabine results in decreased expression of BCL2 protein [alvocidib co-treated with Gemcitabine] results in decreased expression of BCL2 protein; [Aminophylline co-treated with Gemcitabine] results in decreased expression of BCL2 protein; [ICI 118551 co-treated with Gemcitabine] results in decreased expression of BCL2 protein; [Mastic Resin co-treated with Gemcitabine] results in decreased expression of BCL2 protein; [Theophylline co-treated with Gemcitabine] results in decreased expression of BCL2 protein; Gemcitabine inhibits the reaction [Fluorouracil results in decreased expression of BCL2 mRNA]; Gemcitabine inhibits the reaction [Fluorouracil results in decreased expression of BCL2 protein]; U 0126 inhibits the reaction [Gemcitabine results in decreased expression of BCL2 protein] [Curcumin co-treated with Gemcitabine] results in decreased expression of BCL2 protein
CTD
PMID:15476743 PMID:15645133 PMID:15770523 PMID:16929163 PMID:17440100 PMID:20523344 PMID:21570961 More...
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
G
Bcl2l1
Bcl2-like 1
multiple interactions decreases expression
ISO
Gemcitabine inhibits the reaction [Fluorouracil affects the expression of BCL2L1 mRNA]; Gemcitabine inhibits the reaction [Fluorouracil affects the expression of BCL2L1 protein] [Curcumin co-treated with Gemcitabine] results in decreased expression of BCL2L1 protein Gemcitabine results in decreased expression of BCL2L1 protein
CTD
PMID:15476743 PMID:16929163 PMID:17440100
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
G
Bcl2l11
Bcl2-like 11
increases expression
ISO
Gemcitabine results in increased expression of BCL2L11 mRNA
CTD
PMID:17039268
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
G
Bcl6
BCL6, transcription repressor
increases expression
ISO
Gemcitabine results in increased expression of BCL6 mRNA
CTD
PMID:17039268
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
G
Bdnf
brain-derived neurotrophic factor
decreases expression
ISO
Gemcitabine results in decreased expression of BDNF protein
CTD
PMID:20531411
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
G
Bid
BH3 interacting domain death agonist
increases cleavage
ISO
Gemcitabine results in increased cleavage of BID protein
CTD
PMID:14750167
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
G
Birc2
baculoviral IAP repeat-containing 2
increases expression
ISO
Gemcitabine results in increased expression of BIRC2 mRNA
CTD
PMID:17039268
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
G
Birc3
baculoviral IAP repeat-containing 3
multiple interactions affects expression
ISO
[Curcumin co-treated with Gemcitabine] results in decreased expression of BIRC3 protein Gemcitabine affects the expression of BIRC3 mRNA
CTD
PMID:17039268 PMID:17440100
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
G
Birc5
baculoviral IAP repeat-containing 5
multiple interactions
ISO
[Curcumin co-treated with Gemcitabine] results in decreased expression of BIRC5 protein Gemcitabine inhibits the reaction [Fluorouracil results in decreased expression of BIRC5 mRNA]; Gemcitabine inhibits the reaction [Fluorouracil results in decreased expression of BIRC5 protein]
CTD
PMID:16929163 PMID:17440100
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
G
Bnip3l
BCL2 interacting protein 3 like
increases expression
ISO
Gemcitabine results in increased expression of BNIP3L mRNA
CTD
PMID:17039268
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
G
Braf
B-Raf proto-oncogene, serine/threonine kinase
decreases expression
ISO
Gemcitabine results in decreased expression of BRAF mRNA
CTD
PMID:20103597
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
G
Brca1
BRCA1, DNA repair associated
decreases response to substance increases expression
ISO
BRCA1 results in decreased susceptibility to Gemcitabine Gemcitabine results in increased expression of BRCA1 mRNA
CTD
PMID:20103597 PMID:21771338
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
G
Casp3
caspase 3
increases cleavage multiple interactions increases activity increases expression
ISO
Gemcitabine results in increased cleavage of CASP3 protein [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Gemcitabine] affects the activity of CASP3 protein; [3-(4-methylphenylsulfonyl)-2-propenenitrile co-treated with Gemcitabine] affects the activity of CASP3 protein; [alvocidib co-treated with Gemcitabine] results in increased cleavage of CASP3 protein; [Calcitriol co-treated with Gemcitabine] results in increased expression of CASP3 protein; [Gemcitabine co-treated with TNFRSF10B] affects the activity of CASP3 protein; [Vorinostat co-treated with Gemcitabine] results in increased activity of CASP3 protein; Gemcitabine results in increased expression of and results in increased activity of CASP3 protein; licoricidin promotes the reaction [Gemcitabine results in increased activity of CASP3 protein]; licoricidin promotes the reaction [Gemcitabine results in increased expression of and results in increased activity of CASP3 protein]; Quercetin promotes the reaction [Gemcitabine results in increased activity of CASP3 protein]; SMG1 protein inhibits the reaction [Gemcitabine results in increased activity of CASP3 protein] [10-propargyl-10-deazaaminopterin co-treated with Gemcitabine] results in increased activity of CASP3 protein; [Curcumin co-treated with Gemcitabine] results in decreased expression of CASP3 protein Gemcitabine results in increased expression of CASP3 protein modified form
CTD
PMID:12479703 PMID:15476743 PMID:15726400 PMID:15770523 PMID:16153448 PMID:16467107 PMID:17159604 PMID:17440100 PMID:18089714 PMID:20299819 PMID:20699664 PMID:20798217 PMID:21418860 PMID:26050647 PMID:29782821 More...
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
G
Casp6
caspase 6
multiple interactions
ISO
[Calcitriol co-treated with Gemcitabine] results in increased expression of CASP6 protein
CTD
PMID:20699664
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
G
Casp8
caspase 8
increases cleavage increases activity multiple interactions
ISO
Gemcitabine results in increased cleavage of CASP8 protein Gemcitabine results in increased activity of CASP8 protein [Calcitriol co-treated with Gemcitabine] results in increased expression of CASP8 protein; [Gemcitabine co-treated with TNFRSF10B] affects the activity of CASP8 protein; [TNFSF10 co-treated with Gemcitabine] results in increased activity of CASP8 protein; Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein; SFN protein inhibits the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein]; YAP1 protein affects the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein]
CTD
PMID:12479703 PMID:14750167 PMID:17159604 PMID:17671697 PMID:18089714 PMID:20699664 PMID:26894857 More...
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
G
Casp9
caspase 9
multiple interactions increases cleavage increases activity
ISO
[Curcumin co-treated with Gemcitabine] results in decreased expression of CASP9 protein [Calcitriol co-treated with Gemcitabine] results in increased expression of CASP9 protein; Quercetin promotes the reaction [Gemcitabine results in increased activity of CASP9 protein]; SMG1 protein inhibits the reaction [Gemcitabine results in increased activity of CASP9 protein] Gemcitabine results in increased cleavage of CASP9 protein
CTD
PMID:12479703 PMID:15476743 PMID:15726400 PMID:17159604 PMID:17440100 PMID:20699664 PMID:21418860 PMID:26050647 More...
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
G
Ccl2
C-C motif chemokine ligand 2
decreases expression
ISO
Gemcitabine results in decreased expression of CCL2 protein
CTD
PMID:20531411
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
G
Ccl20
C-C motif chemokine ligand 20
increases expression
ISO
Gemcitabine results in increased expression of CCL20 mRNA
CTD
PMID:17039268
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
G
Ccl3
C-C motif chemokine ligand 3
increases expression
ISO
Gemcitabine results in increased expression of CCL3 protein
CTD
PMID:20531411
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
G
Ccnb1
cyclin B1
decreases expression increases expression
ISO
Gemcitabine results in decreased expression of CCNB1 mRNA Gemcitabine results in increased expression of CCNB1 protein
CTD
PMID:11504793 PMID:20103597
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
G
Ccnd1
cyclin D1
multiple interactions decreases expression
ISO
[Curcumin co-treated with Gemcitabine] results in decreased expression of CCND1 protein Celecoxib promotes the reaction [Gemcitabine results in decreased expression of CCND1 protein] Gemcitabine results in decreased expression of CCND1 mRNA; Gemcitabine results in decreased expression of CCND1 protein
CTD
PMID:16060994 PMID:17039268 PMID:17440100
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
G
Ccng2
cyclin G2
increases expression
ISO
Gemcitabine results in increased expression of CCNG2 mRNA
CTD
PMID:17039268
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
G
Cd274
CD274 molecule
multiple interactions
ISO
[Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; [Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; Gemcitabine inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; Gemcitabine inhibits the reaction [IL1B protein results in increased expression of CD274 protein]
CTD
PMID:32894642
NCBI chr 1:227,116,627...227,137,379
Ensembl chr 1:227,116,649...227,134,450
G
Cd40
CD40 molecule
decreases expression
ISO
Gemcitabine results in decreased expression of CD40 mRNA; Gemcitabine results in decreased expression of CD40 protein
CTD
PMID:17039268 PMID:20531411
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
G
Cd40lg
CD40 ligand
decreases expression
ISO
Gemcitabine results in decreased expression of CD40LG protein
CTD
PMID:20531411
NCBI chr X:135,127,119...135,138,302
Ensembl chr X:135,126,969...135,138,306
G
Cd44
CD44 molecule (Indian blood group)
affects expression
ISO
Gemcitabine affects the expression of CD44 mRNA
CTD
PMID:35063459
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
G
Cda
cytidine deaminase
affects response to substance multiple interactions
ISO
CDA protein affects the susceptibility to Gemcitabine [Crizotinib results in decreased expression of CDA protein] which results in increased susceptibility to Gemcitabine; CDA protein affects the susceptibility to [Gemcitabine co-treated with Mitomycin]; CDA protein affects the susceptibility to [Gemcitabine co-treated with Oxaliplatin]
CTD
PMID:18728667 PMID:22973962
NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231
G
Cdc25c
cell division cycle 25C
multiple interactions
ISO
[Gemcitabine co-treated with ON 01910] results in decreased expression of CDC25C protein
CTD
PMID:20103597
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
G
Cdh1
cadherin 1
increases expression
ISO
Gemcitabine results in increased expression of CDH1 mRNA
CTD
PMID:17039268
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
G
Cdkn1a
cyclin-dependent kinase inhibitor 1A
increases expression multiple interactions
ISO
Gemcitabine results in increased expression of CDKN1A mRNA; Gemcitabine results in increased expression of CDKN1A protein [alvocidib co-treated with Gemcitabine] results in increased expression of CDKN1A protein; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of CDKN1A protein; Nicotine inhibits the reaction [Gemcitabine results in increased expression of CDKN1A protein]
CTD
PMID:15476743 PMID:15770523 PMID:16601104 PMID:17039268 PMID:25189999
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
G
Cdkn1b
cyclin-dependent kinase inhibitor 1B
decreases response to substance
ISO
CDKN1B results in decreased susceptibility to Gemcitabine
CTD
PMID:21652059
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
G
Cebpb
CCAAT/enhancer binding protein beta
increases expression
ISO
Gemcitabine results in increased expression of CEBPB mRNA
CTD
PMID:17039268
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
G
Chrdl2
chordin-like 2
multiple interactions
ISO
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CHRDL2 protein
CTD
PMID:24979617
NCBI chr 1:154,343,201...154,370,651
Ensembl chr 1:154,343,201...154,370,640
G
Ckb
creatine kinase B
decreases expression
ISO
Gemcitabine results in decreased expression of CKB mRNA
CTD
PMID:17039268
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
G
Clic4
chloride intracellular channel 4
increases expression
ISO
Gemcitabine results in increased expression of CLIC4 mRNA
CTD
PMID:17039268
NCBI chr 5:147,456,819...147,513,278
Ensembl chr 5:147,453,712...147,513,452
G
Clu
clusterin
increases expression affects response to substance
ISO
Gemcitabine results in increased expression of CLU protein CLU protein affects the susceptibility to Gemcitabine
CTD
PMID:19007378
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
G
Cnr1
cannabinoid receptor 1
multiple interactions increases expression
ISO
BAY 11-7085 inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA]; Dactinomycin inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Gemcitabine results in increased expression of CNR1 mRNA]
CTD
PMID:21525939
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
G
Cnr2
cannabinoid receptor 2
multiple interactions increases expression
ISO
BAY 11-7085 inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA]; Dactinomycin inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Gemcitabine results in increased expression of CNR2 mRNA]
CTD
PMID:21525939
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
G
Csf2
colony stimulating factor 2
decreases expression
ISO
Gemcitabine results in decreased expression of CSF2 protein
CTD
PMID:20531411
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
G
Csf3
colony stimulating factor 3
decreases expression
ISO
Gemcitabine results in decreased expression of CSF3 protein
CTD
PMID:20531411
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
G
Csrp2
cysteine and glycine-rich protein 2
increases expression
ISO
Gemcitabine results in increased expression of CSRP2 mRNA
CTD
PMID:17039268
NCBI chr 7:46,349,109...46,367,743
Ensembl chr 7:46,348,686...46,367,745
G
Cthrc1
collagen triple helix repeat containing 1
increases expression
ISO
Gemcitabine results in increased expression of CTHRC1 mRNA
CTD
PMID:17039268
NCBI chr 7:70,122,474...70,132,756
Ensembl chr 7:70,122,474...70,132,756
G
Ctnnb1
catenin beta 1
increases expression
ISO
Gemcitabine results in increased expression of CTNNB1 mRNA
CTD
PMID:25605917
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
G
Cxcl1
C-X-C motif chemokine ligand 1
increases expression
ISO
Gemcitabine results in increased expression of CXCL1 mRNA
CTD
PMID:17039268
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
G
Cxcl11
C-X-C motif chemokine ligand 11
multiple interactions
ISO
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CXCL11 protein
CTD
PMID:24979617
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
G
Cxcl2
C-X-C motif chemokine ligand 2
increases expression
ISO
Gemcitabine results in increased expression of CXCL2 mRNA
CTD
PMID:17039268
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
G
Cxcl3
C-X-C motif chemokine ligand 3
increases expression
ISO
Gemcitabine results in increased expression of CXCL1 mRNA
CTD
PMID:17039268
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
G
Cxcr4
C-X-C motif chemokine receptor 4
affects expression
ISO
Gemcitabine affects the expression of CXCR4 mRNA
CTD
PMID:20103597
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
G
Cyp24a1
cytochrome P450, family 24, subfamily a, polypeptide 1
decreases expression
ISO
Gemcitabine results in decreased expression of CYP24A1 mRNA
CTD
PMID:17039268
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
G
Ddit4
DNA-damage-inducible transcript 4
affects expression
ISO
Gemcitabine affects the expression of DDIT4 mRNA
CTD
PMID:17039268
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
G
Dhx9
DExH-box helicase 9
decreases expression
ISO
Gemcitabine results in decreased expression of DHX9 mRNA
CTD
PMID:17039268
NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069
G
Dlg2
discs large MAGUK scaffold protein 2
increases expression
ISO
Gemcitabine results in increased expression of DLG2 mRNA
CTD
PMID:17039268
NCBI chr 1:144,451,653...146,503,949
Ensembl chr 1:144,451,472...146,499,475
G
Dnmt1
DNA methyltransferase 1
multiple interactions
ISO
[DNMT1 protein binds to SFN promoter] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; [Gemcitabine results in decreased susceptibility to Gemcitabine] inhibits the reaction [DNMT1 protein binds to SFN promoter]; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of DNMT1 protein; [UHRF1 protein promotes the reaction [DNMT1 protein binds to SFN promoter]] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; DNMT1 protein inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]
CTD
PMID:25189999
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
G
Dnmt3b
DNA methyltransferase 3 beta
multiple interactions
ISO
[Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of DNMT3B protein
CTD
PMID:25189999
NCBI chr 3:142,130,592...142,169,124
Ensembl chr 3:142,130,592...142,169,124
G
Dpyd
dihydropyrimidine dehydrogenase
multiple interactions
ISO
[TYMP protein co-treated with DPYD protein] affects the susceptibility to Gemcitabine
CTD
PMID:18728667
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
G
Dync1h1
dynein cytoplasmic 1 heavy chain 1
decreases expression
ISO
Gemcitabine results in decreased expression of DYNC1H1 mRNA
CTD
PMID:17039268
NCBI chr 6:129,615,208...129,680,888
Ensembl chr 6:129,609,397...129,680,883
G
Edn1
endothelin 1
decreases expression
ISO
Gemcitabine results in decreased expression of EDN1 protein
CTD
PMID:20531411
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
G
Edn2
endothelin 2
decreases expression
ISO
Gemcitabine results in decreased expression of EDN2 mRNA
CTD
PMID:17039268
NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814
G
Egf
epidermal growth factor
multiple interactions decreases expression
ISO
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; U 0126 inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]] Gemcitabine results in decreased expression of EGF protein
CTD
PMID:20531411 PMID:21613822
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
G
Egfr
epidermal growth factor receptor
multiple interactions increases degradation increases phosphorylation increases expression decreases expression
ISO
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; EGFR gene mutant form results in increased susceptibility to [Gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]; Gefitinib inhibits the reaction [Gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; Gemcitabine promotes the reaction [HER3 protein binds to EGFR protein] Gemcitabine results in increased degradation of EGFR protein Gemcitabine results in increased phosphorylation of EGFR protein Gemcitabine results in increased expression of EGFR mRNA Gemcitabine results in decreased expression of EGFR mRNA; Gemcitabine results in decreased expression of EGFR protein
CTD
PMID:17146438 PMID:20103597 PMID:20726858 PMID:21541241
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
G
Egr1
early growth response 1
increases expression
ISO
Gemcitabine results in increased expression of EGR1 mRNA
CTD
PMID:17039268
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
G
Esr1
estrogen receptor 1
multiple interactions
ISO
Gemcitabine binds to and results in decreased activity of ESR1 protein
CTD
PMID:25752796
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Etv1
ETS variant transcription factor 1
increases expression
ISO
Gemcitabine results in increased expression of ETV1 mRNA
CTD
PMID:17039268
NCBI chr 6:55,590,149...55,681,784
Ensembl chr 6:55,590,234...55,681,775
G
Evi2b
ecotropic viral integration site 2B
decreases expression
ISO
Gemcitabine results in decreased expression of EVI2B mRNA
CTD
PMID:17039268
NCBI chr10:64,472,693...64,474,311
Ensembl chr10:64,471,505...64,481,560
G
F7
coagulation factor VII
decreases expression
ISO
Gemcitabine results in decreased expression of F7 protein
CTD
PMID:20531411
NCBI chr16:76,489,779...76,500,636
Ensembl chr16:76,489,717...76,500,610
G
Fas
Fas cell surface death receptor
increases expression
ISO
Gemcitabine results in increased expression of FAS mRNA; Gemcitabine results in increased expression of FAS protein
CTD
PMID:11138460 PMID:17159604
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
G
Fbxo25
F-box protein 25
increases expression
ISO
Gemcitabine results in increased expression of FBXO25 mRNA
CTD
PMID:17039268
NCBI chr16:75,666,062...75,701,770
Ensembl chr16:75,667,904...75,701,696
G
Fgf2
fibroblast growth factor 2
increases expression multiple interactions
ISO
Gemcitabine results in increased expression of FGF2 protein [Gemcitabine co-treated with IFNA2 protein] results in increased expression of FGF2 protein
CTD
PMID:12738744 PMID:20531411
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
G
Fgg
fibrinogen gamma chain
affects expression
ISO
Gemcitabine affects the expression of FGG mRNA
CTD
PMID:17039268
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
G
Fosl2
FOS like 2, AP-1 transcription factor subunit
decreases expression
ISO
Gemcitabine results in decreased expression of FOSL2 mRNA
CTD
PMID:17039268
NCBI chr 6:24,297,898...24,319,157
Ensembl chr 6:24,300,956...24,320,034
G
Fxyd3
FXYD domain-containing ion transport regulator 3
increases expression
ISO
Gemcitabine results in increased expression of FXYD3 mRNA
CTD
PMID:17039268
NCBI chr 1:86,305,531...86,312,455
G
Gal3st1
galactose-3-O-sulfotransferase 1
decreases expression
ISO
Gemcitabine results in decreased expression of GAL3ST1 mRNA
CTD
PMID:17039268
NCBI chr14:78,868,049...78,886,402
Ensembl chr14:78,870,793...78,886,388
G
Gas1
growth arrest-specific 1
decreases expression
ISO
Gemcitabine results in decreased expression of GAS1 mRNA
CTD
PMID:17039268
NCBI chr17:4,482,014...4,485,155
G
Gask1b
golgi associated kinase 1B
decreases expression
ISO
Gemcitabine results in decreased expression of GASK1B mRNA
CTD
PMID:17039268
NCBI chr 2:165,047,689...165,112,479
Ensembl chr 2:165,047,684...165,112,477
G
Gdf15
growth differentiation factor 15
multiple interactions
ISO
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of GDF15 protein
CTD
PMID:24979617
NCBI chr16:18,805,312...18,807,893
Ensembl chr16:18,805,239...18,808,055
G
Gipc1
GIPC PDZ domain containing family, member 1
affects response to substance
ISO
GIPC1 affects the susceptibility to Gemcitabine
CTD
PMID:25469510
NCBI chr19:24,474,291...24,487,083
Ensembl chr19:24,453,123...24,486,997
G
Gli2
GLI family zinc finger 2
affects expression
ISO
Gemcitabine affects the expression of GLI2 mRNA
CTD
PMID:20103597
NCBI chr13:29,946,809...30,163,901
Ensembl chr13:29,946,809...30,163,574
G
Glrx
glutaredoxin
increases expression
ISO
Gemcitabine results in increased expression of GLRX mRNA
CTD
PMID:17039268
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
G
Gpc3
glypican 3
increases expression
ISO
Gemcitabine results in increased expression of GPC3 mRNA
CTD
PMID:17039268
NCBI chr X:131,868,983...132,236,837
Ensembl chr X:131,868,990...132,236,798
G
Gsk3b
glycogen synthase kinase 3 beta
increases phosphorylation
ISO
Gemcitabine results in increased phosphorylation of GSK3B protein
CTD
PMID:16570353
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
G
Gtf2a1
general transcription factor 2A subunit 1
affects expression
ISO
Gemcitabine affects the expression of GTF2A1 mRNA
CTD
PMID:17039268
NCBI chr 6:110,488,891...110,521,059
Ensembl chr 6:110,488,931...110,521,511
G
H4c3
H4 clustered histone 3
decreases expression
ISO
Gemcitabine results in decreased expression of H4C3 mRNA
CTD
PMID:17039268
G
Hdac9
histone deacetylase 9
increases expression
ISO
Gemcitabine results in increased expression of HDAC9 mRNA
CTD
PMID:17039268
NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333
G
Hif1a
hypoxia inducible factor 1 subunit alpha
affects response to substance
ISO
HIF1A protein affects the susceptibility to Gemcitabine
CTD
PMID:16628086
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
G
Hist2h4
histone cluster 2, H4
decreases expression
ISO
Gemcitabine results in decreased expression of H4C2 mRNA
CTD
PMID:17039268
NCBI chr 2:183,831,601...183,831,996
Ensembl chr 2:183,825,994...183,832,048
G
Hmox1
heme oxygenase 1
multiple interactions increases expression
ISO
CASC9 protein affects the reaction [Gemcitabine results in increased expression of HMOX1 mRNA]; CASC9 protein affects the reaction [Gemcitabine results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of HMOX1 mRNA] Gemcitabine results in increased expression of HMOX1 mRNA; Gemcitabine results in increased expression of HMOX1 protein
CTD
PMID:35913601
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
G
Hoxb2
homeobox B2
increases expression
ISO
Gemcitabine results in increased expression of HOXB2 mRNA
CTD
PMID:17039268
NCBI chr10:81,317,927...81,320,223
Ensembl chr10:81,318,026...81,320,192
G
Hspa1l
heat shock protein family A (Hsp70) member 1 like
decreases expression
ISO
Gemcitabine results in decreased expression of HSPA1L mRNA
CTD
PMID:17039268
NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571
G
Hspa5
heat shock protein family A (Hsp70) member 5
increases expression
ISO
Gemcitabine results in increased expression of HSPA5 mRNA
CTD
PMID:17039268
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
G
Icam1
intercellular adhesion molecule 1
decreases expression multiple interactions
ISO
Gemcitabine results in decreased expression of ICAM1 protein [Curcumin co-treated with Gemcitabine] results in decreased expression of ICAM1 protein
CTD
PMID:17440100 PMID:20531411
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
G
Ifng
interferon gamma
decreases expression
ISO
Gemcitabine results in decreased expression of IFNG protein
CTD
PMID:20531411
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
G
Igf1r
insulin-like growth factor 1 receptor
decreases expression
ISO
Gemcitabine results in decreased expression of IGF1R mRNA
CTD
PMID:20103597
NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
G
Igfbp3
insulin-like growth factor binding protein 3
affects expression
ISO
Gemcitabine affects the expression of IGFBP3 mRNA
CTD
PMID:20103597
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
G
Il10
interleukin 10
decreases expression
ISO
Gemcitabine results in decreased expression of IL10 protein
CTD
PMID:20531411
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
G
Il13
interleukin 13
increases expression
ISO
Gemcitabine results in increased expression of IL13 protein
CTD
PMID:20531411
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
G
Il15
interleukin 15
decreases expression
ISO
Gemcitabine results in decreased expression of IL15 protein
CTD
PMID:20531411
NCBI chr19:25,640,013...25,706,818
Ensembl chr19:25,640,251...25,706,820
G
Il16
interleukin 16
increases expression
ISO
Gemcitabine results in increased expression of IL16 protein
CTD
PMID:20531411
NCBI chr 1:137,617,702...137,718,022
Ensembl chr 1:137,617,944...137,718,130
G
Il1a
interleukin 1 alpha
decreases expression
ISO
Gemcitabine results in decreased expression of IL1A protein
CTD
PMID:20531411
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
G
Il1b
interleukin 1 beta
decreases expression multiple interactions
ISO
Gemcitabine results in decreased expression of IL1B protein [Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; [Oleanolic Acid co-treated with Gemcitabine] inhibits the reaction [IL1B protein results in increased expression of CD274 protein]; Gemcitabine inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]; Gemcitabine inhibits the reaction [IL1B protein results in increased expression of CD274 protein]
CTD
PMID:20531411 PMID:32894642
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Il4
interleukin 4
decreases expression
ISO
Gemcitabine results in decreased expression of IL4 protein
CTD
PMID:20531411
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
G
Il6
interleukin 6
increases secretion decreases expression increases expression
ISO
Gemcitabine results in increased secretion of IL6 protein Gemcitabine results in decreased expression of IL6 protein Gemcitabine results in increased expression of IL6 mRNA
CTD
PMID:17039268 PMID:20531411 PMID:28007550
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Ilk
integrin-linked kinase
affects response to substance
ISO
ILK protein affects the susceptibility to Gemcitabine
CTD
PMID:15867245
NCBI chr 1:160,088,839...160,095,140
Ensembl chr 1:160,088,897...160,095,140
G
Ins2
insulin 2
increases expression
ISO
Gemcitabine results in increased expression of INS protein
CTD
PMID:20531411
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
G
Insig1
insulin induced gene 1
increases expression
ISO
Gemcitabine results in increased expression of INSIG1 mRNA
CTD
PMID:17039268
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
G
Iqgap1
IQ motif containing GTPase activating protein 1
increases expression
ISO
Gemcitabine results in increased expression of IQGAP1 mRNA
CTD
PMID:17039268
NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755
G
Irak2
interleukin-1 receptor-associated kinase 2
increases expression
ISO
Gemcitabine results in increased expression of IRAK2 mRNA
CTD
PMID:17039268
NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602
G
Irf3
interferon regulatory factor 3
decreases expression
ISO
Gemcitabine results in decreased expression of IRF3 mRNA
CTD
PMID:17039268
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
G
Itgav
integrin subunit alpha V
multiple interactions
ISO
[ITGB6 co-treated with ITGAV] affects the susceptibility to Gemcitabine
CTD
PMID:20150628
NCBI chr 3:68,838,524...68,926,653
Ensembl chr 3:68,838,189...68,926,639
G
Itgb6
integrin subunit beta 6
multiple interactions
ISO
[ITGB6 co-treated with ITGAV] affects the susceptibility to Gemcitabine
CTD
PMID:20150628
NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
G
Itsn2
intersectin 2
increases expression
ISO
Gemcitabine results in increased expression of ITSN2 mRNA
CTD
PMID:17039268
NCBI chr 6:27,616,645...27,727,373
Ensembl chr 6:27,600,406...27,727,124
G
Jam3
junctional adhesion molecule 3
decreases expression
ISO
Gemcitabine results in decreased expression of JAM3 mRNA
CTD
PMID:17039268
NCBI chr 8:25,508,461...25,569,306
Ensembl chr 8:25,507,057...25,569,355
G
Jun
Jun proto-oncogene, AP-1 transcription factor subunit
multiple interactions
ISO
[Copper co-treated with Disulfiram co-treated with Gemcitabine] results in increased expression of and results in increased phosphorylation of JUN protein
CTD
PMID:23033007
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
G
Kctd12
potassium channel tetramerization domain containing 12
decreases expression
ISO
Gemcitabine results in decreased expression of KCTD12 mRNA
CTD
PMID:17039268
NCBI chr15:79,800,077...79,806,064
Ensembl chr15:79,801,191...79,806,282
G
Kitlg
KIT ligand
multiple interactions decreases expression
ISO
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of KITLG protein Gemcitabine results in decreased expression of KITLG protein
CTD
PMID:20531411 PMID:24979617
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
G
Klf8
KLF transcription factor 8
increases expression
ISO
Gemcitabine results in increased expression of KLF8 mRNA
CTD
PMID:17039268
NCBI chr X:17,950,045...18,132,980
Ensembl chr X:17,958,843...18,133,182
G
Krt8
keratin 8
decreases expression
ISO
Gemcitabine results in decreased expression of KRT8 mRNA
CTD
PMID:17039268
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
G
Larp4b
La ribonucleoprotein 4B
increases expression
ISO
Gemcitabine results in increased expression of LARP4B mRNA
CTD
PMID:17039268
NCBI chr17:61,138,709...61,217,423
Ensembl chr17:61,138,709...61,187,960
G
Lep
leptin
decreases expression
ISO
Gemcitabine results in decreased expression of LEP protein
CTD
PMID:20531411
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
G
Lifr
LIF receptor subunit alpha
increases expression
ISO
Gemcitabine results in increased expression of LIFR mRNA
CTD
PMID:17039268
NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699
G
Lpar6
lysophosphatidic acid receptor 6
decreases expression
ISO
Gemcitabine results in decreased expression of LPAR6 mRNA
CTD
PMID:17039268
NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331
G
Lrrc28
leucine rich repeat containing 28
increases expression
ISO
Gemcitabine results in increased expression of LRRC28 mRNA
CTD
PMID:17039268
NCBI chr 1:121,116,833...121,245,805
Ensembl chr 1:121,127,733...121,245,784
G
Lta
lymphotoxin alpha
increases expression
ISO
Gemcitabine results in increased expression of LTA protein
CTD
PMID:20531411
NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859
G
Lyz2
lysozyme 2
decreases expression
ISO
Gemcitabine results in decreased expression of LYZ mRNA
CTD
PMID:17039268
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
G
Maf
MAF bZIP transcription factor
increases expression
ISO
Gemcitabine results in increased expression of MAF mRNA
CTD
PMID:17039268
NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365
G
Magea10
MAGE family member A10
decreases expression
ISO
Gemcitabine results in decreased expression of MAGEA10 mRNA
CTD
PMID:17039268
NCBI chr X:150,212,001...150,218,253
Ensembl chr X:150,213,245...150,214,213
G
Magi1
membrane associated guanylate kinase, WW and PDZ domain containing 1
increases expression
ISO
Gemcitabine results in increased expression of MAGI1 mRNA
CTD
PMID:17039268
NCBI chr 4:126,205,667...126,811,354
Ensembl chr 4:126,206,816...126,811,691
G
Map2k3
mitogen activated protein kinase kinase 3
increases phosphorylation
ISO
Gemcitabine results in increased phosphorylation of MAP2K3 protein
CTD
PMID:15003513
NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492
G
Map2k6
mitogen-activated protein kinase kinase 6
increases phosphorylation
ISO
Gemcitabine results in increased phosphorylation of MAP2K6 protein
CTD
PMID:15003513
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
G
Mapk1
mitogen activated protein kinase 1
increases phosphorylation multiple interactions
ISO
Gemcitabine results in increased phosphorylation of MAPK1 protein [Copper co-treated with Disulfiram co-treated with Gemcitabine] results in increased phosphorylation of MAPK1 protein
CTD
PMID:15476743 PMID:23033007
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
G
Mapk3
mitogen activated protein kinase 3
increases phosphorylation multiple interactions
ISO
Gemcitabine results in increased phosphorylation of MAPK3 protein [Copper co-treated with Disulfiram co-treated with Gemcitabine] results in increased phosphorylation of MAPK3 protein
CTD
PMID:15476743 PMID:23033007
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
G
Marcks
myristoylated alanine rich protein kinase C substrate
increases expression increases phosphorylation
ISO
Gemcitabine results in increased expression of MARCKS mRNA Gemcitabine results in increased phosphorylation of MARCKS protein
CTD
PMID:9523737 PMID:17039268
NCBI chr20:40,685,315...40,691,012
Ensembl chr20:40,685,315...40,691,012
G
Mars1
methionyl-tRNA synthetase 1
increases expression
ISO
Gemcitabine results in increased expression of MARS1 mRNA
CTD
PMID:17039268
NCBI chr 7:63,121,142...63,138,550
Ensembl chr 7:63,121,142...63,138,495
G
Mdm2
MDM2 proto-oncogene
increases expression decreases expression
ISO
Gemcitabine results in increased expression of MDM2 mRNA Gemcitabine results in decreased expression of MDM2 mRNA
CTD
PMID:17039268 PMID:20103597
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
G
Mgmt
O-6-methylguanine-DNA methyltransferase
decreases expression
ISO
Gemcitabine results in decreased expression of MGMT mRNA
CTD
PMID:17039268
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
G
Mir222
microRNA 222
affects response to substance
ISO
MIR222 mRNA affects the susceptibility to Gemcitabine
CTD
PMID:35974258
NCBI chr X:3,428,904...3,429,006
Ensembl chr X:3,428,904...3,429,006
G
Mir24-2
microRNA 24-2
multiple interactions
ISO
MIR24-2 mRNA affects the susceptibility to [Betulinic Acid co-treated with Gemcitabine]
CTD
PMID:25841339
NCBI chr19:23,954,683...23,954,790
Ensembl chr19:23,954,683...23,954,790
G
Mki67
marker of proliferation Ki-67
multiple interactions
ISO
[Curcumin co-treated with Gemcitabine] results in decreased expression of MKI67 protein
CTD
PMID:17440100
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
G
Mmp3
matrix metallopeptidase 3
decreases expression
ISO
Gemcitabine results in decreased expression of MMP3 protein
CTD
PMID:20531411
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
G
Mmp9
matrix metallopeptidase 9
multiple interactions
ISO
[Gemcitabine co-treated with IFNA2 protein] results in increased expression of MMP9 protein [Curcumin co-treated with Gemcitabine] results in decreased expression of MMP9 protein
CTD
PMID:12738744 PMID:17440100
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
G
Mpo
myeloperoxidase
increases expression
ISO
Gemcitabine results in increased expression of MPO protein
CTD
PMID:20531411
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
G
Msln
mesothelin
multiple interactions
EXP
Gemcitabine results in decreased expression of and results in decreased secretion of MSLN protein alternative form
CTD
PMID:25347530
NCBI chr10:14,771,946...14,781,382
Ensembl chr10:14,771,961...14,777,643
G
Mt-co3
mitochondrially encoded cytochrome c oxidase III
multiple interactions decreases response to substance
ISO
Sodium Azide inhibits the reaction [COX3 protein results in decreased susceptibility to Gemcitabine]
CTD
PMID:17428446
NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382
G
Mxi1
MAX interactor 1, dimerization protein
increases expression
ISO
Gemcitabine results in increased expression of MXI1 mRNA
CTD
PMID:17039268
NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:252,323,303...252,383,681
G
Myb
MYB proto-oncogene, transcription factor
increases expression
ISO
Gemcitabine results in increased expression of MYB mRNA
CTD
PMID:17039268
NCBI chr 1:15,939,771...15,973,367
Ensembl chr 1:15,939,761...15,973,057
G
Myc
MYC proto-oncogene, bHLH transcription factor
multiple interactions affects response to substance
ISO
[Oligonucleotides binds to MYC gene] which results in increased susceptibility to Gemcitabine MYC affects the susceptibility to Gemcitabine [Curcumin co-treated with Gemcitabine] results in decreased expression of MYC protein
CTD
PMID:17440100 PMID:23681918
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
G
Nanog
Nanog homeobox
decreases expression
ISO
Gemcitabine results in decreased expression of NANOG mRNA
CTD
PMID:25605917 PMID:35063459
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
G
Ncbp1
nuclear cap binding protein subunit 1
increases expression
ISO
Gemcitabine results in increased expression of NCBP1 mRNA
CTD
PMID:17039268
NCBI chr 5:60,416,023...60,449,004
Ensembl chr 5:60,415,982...60,449,089
G
Nedd9
neural precursor cell expressed, developmentally down-regulated 9
increases expression
ISO
Gemcitabine results in increased expression of NEDD9 mRNA
CTD
PMID:17039268
NCBI chr17:23,289,793...23,468,026
Ensembl chr17:23,282,326...23,468,019
G
Neu1
neuraminidase 1
increases expression
ISO
Gemcitabine results in increased expression of NEU1 mRNA
CTD
PMID:17039268
NCBI chr20:3,897,480...3,901,745
Ensembl chr20:3,897,480...3,901,745
G
Nfe2l2
NFE2 like bZIP transcription factor 2
decreases response to substance multiple interactions increases expression
ISO
NFE2L2 protein results in decreased susceptibility to Gemcitabine CASC9 protein affects the reaction [Gemcitabine results in increased expression of NFE2L2 mRNA]; CASC9 protein affects the reaction [Gemcitabine results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of CASC9 mRNA]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of NQO1 mRNA] Gemcitabine results in increased expression of NFE2L2 mRNA; Gemcitabine results in increased expression of NFE2L2 protein
CTD
PMID:21489257 PMID:35913601
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
G
Nfkb2
nuclear factor kappa B subunit 2
affects expression
ISO
Gemcitabine affects the expression of NFKB2 mRNA
CTD
PMID:17039268
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
G
Nfkbia
NFKB inhibitor alpha
multiple interactions
ISO
[Mastic Resin co-treated with Gemcitabine] results in increased expression of NFKBIA protein
CTD
PMID:20523344
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
G
Nfkbie
NFKB inhibitor epsilon
affects expression
ISO
Gemcitabine affects the expression of NFKBIE mRNA
CTD
PMID:17039268
NCBI chr 9:15,443,600...15,450,437
Ensembl chr 9:15,436,941...15,450,437
G
Nnmt
nicotinamide N-methyltransferase
increases expression
ISO
Gemcitabine results in increased expression of NNMT mRNA
CTD
PMID:17039268
NCBI chr 8:48,928,663...48,947,734
Ensembl chr 8:48,933,598...48,946,655
G
Notch1
notch receptor 1
multiple interactions increases expression
ISO
sulforaphane inhibits the reaction [Gemcitabine results in increased expression of NOTCH1 protein]
CTD
PMID:20940707
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
G
Npepps
aminopeptidase puromycin sensitive
decreases expression
ISO
Gemcitabine results in decreased expression of NPEPPS mRNA
CTD
PMID:17039268
NCBI chr10:82,191,454...82,273,967
Ensembl chr10:82,191,456...82,273,967
G
Npm1
nucleophosmin 1
decreases response to substance
ISO
NPM1 protein results in decreased susceptibility to Gemcitabine
CTD
PMID:24736981
NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645
G
Nqo1
NAD(P)H quinone dehydrogenase 1
multiple interactions increases expression
ISO
CASC9 protein affects the reaction [Gemcitabine results in increased expression of NQO1 mRNA]; CASC9 protein affects the reaction [Gemcitabine results in increased expression of NQO1 protein]; NFE2L2 protein affects the reaction [Gemcitabine results in increased expression of NQO1 mRNA] Gemcitabine results in increased expression of NQO1 mRNA; Gemcitabine results in increased expression of NQO1 protein
CTD
PMID:35913601
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
G
Nr4a3
nuclear receptor subfamily 4, group A, member 3
increases expression
ISO
Gemcitabine results in increased expression of NR4A3 mRNA
CTD
PMID:17039268
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
G
Nrg1
neuregulin 1
increases expression
ISO
Gemcitabine results in increased expression of NRG1 mRNA
CTD
PMID:17039268
NCBI chr16:59,250,658...60,303,024
Ensembl chr16:59,250,854...60,296,884
G
Nrp1
neuropilin 1
decreases response to substance
ISO
NRP1 protein results in decreased susceptibility to Gemcitabine
CTD
PMID:15956974
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
G
Nupr1
nuclear protein 1, transcriptional regulator
decreases expression affects response to substance
ISO
Gemcitabine results in decreased expression of NUPR1 mRNA NUPR1 affects the susceptibility to Gemcitabine
CTD
PMID:16397047
NCBI chr 1:181,213,292...181,215,327
G
Or4d6
olfactory receptor family 4 subfamily D member 6
affects response to substance
ISO
OR4D6 gene SNP affects the susceptibility to Gemcitabine
CTD
PMID:26378035
NCBI chr 1:209,039,073...209,040,017
Ensembl chr 1:209,037,992...209,045,985
G
Osm
oncostatin M
multiple interactions
ISO
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of OSM protein
CTD
PMID:24979617
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
G
Pappa
pappalysin
decreases expression
ISO
Gemcitabine results in decreased expression of PAPPA protein
CTD
PMID:20531411
NCBI chr 5:78,497,660...78,735,873
Ensembl chr 5:78,498,300...78,730,666
G
Paqr8
progestin and adipoQ receptor family member 8
increases expression
ISO
Gemcitabine results in increased expression of PAQR8 mRNA
CTD
PMID:17039268
NCBI chr 9:23,312,521...23,362,175
Ensembl chr 9:23,312,585...23,362,340
G
Parp1
poly (ADP-ribose) polymerase 1
increases cleavage multiple interactions
ISO
Gemcitabine results in increased cleavage of PARP1 protein [alvocidib co-treated with Gemcitabine] results in increased cleavage of PARP1 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Gemcitabine results in increased cleavage of PARP1 protein]; SFN protein inhibits the reaction [Gemcitabine results in increased cleavage of PARP1 protein]; YAP1 protein affects the reaction [Gemcitabine results in increased cleavage of PARP1 protein]
CTD
PMID:15770523 PMID:17146438 PMID:26894857
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
G
Parp2
poly (ADP-ribose) polymerase 2
decreases response to substance
ISO
PARP2 protein results in decreased susceptibility to Gemcitabine
CTD
PMID:20798217
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
G
Pcsk9
proprotein convertase subtilisin/kexin type 9
increases expression
ISO
Gemcitabine results in increased expression of PCSK9 mRNA
CTD
PMID:17039268
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
G
Pdpk1
3-phosphoinositide dependent protein kinase-1
decreases response to substance
ISO
PDPK1 protein modified form results in decreased susceptibility to Gemcitabine
CTD
PMID:16782806
NCBI chr10:13,105,435...13,182,664
Ensembl chr10:13,105,498...13,174,623
G
Pdzk1ip1
PDZK1 interacting protein 1
increases expression
ISO
Gemcitabine results in increased expression of PDZK1IP1 mRNA
CTD
PMID:17039268
NCBI chr 5:128,618,050...128,623,131
Ensembl chr 5:128,618,237...128,623,131
G
Pecam1
platelet and endothelial cell adhesion molecule 1
multiple interactions
ISO
Gemcitabine promotes the reaction [Curcumin results in decreased expression of PECAM1 protein]
CTD
PMID:17440100
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
G
Pgr
progesterone receptor
multiple interactions
ISO
Gemcitabine binds to and results in decreased activity of PGR protein
CTD
PMID:25752796
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
G
Pja2
praja ring finger ubiquitin ligase 2
increases expression
ISO
Gemcitabine results in increased expression of PJA2 mRNA
CTD
PMID:17039268
NCBI chr 9:103,956,678...104,006,763
Ensembl chr 9:103,956,678...104,006,783
G
Plau
plasminogen activator, urokinase
increases expression
ISO
Gemcitabine results in increased expression of PLAU mRNA
CTD
PMID:17039268
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
G
Plk1
polo-like kinase 1
decreases expression affects response to substance multiple interactions
ISO
Gemcitabine results in decreased expression of PLK1; Gemcitabine results in decreased expression of PLK1 mRNA PLK1 protein affects the susceptibility to Gemcitabine [Gemcitabine results in decreased expression of PLK1] which results in increased susceptibility to Gemcitabine; ON 01910 promotes the reaction [PLK1 protein affects the susceptibility to Gemcitabine]
CTD
PMID:20103597
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
G
Pou5f1
POU class 5 homeobox 1
decreases expression
ISO
Gemcitabine results in decreased expression of POU5F1 mRNA
CTD
PMID:35063459
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
G
Ppara
peroxisome proliferator activated receptor alpha
affects expression
ISO
Gemcitabine affects the expression of PPARA mRNA
CTD
PMID:19427843
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
G
Ppard
peroxisome proliferator-activated receptor delta
affects expression
ISO
Gemcitabine affects the expression of PPARD mRNA
CTD
PMID:19427843
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
G
Pparg
peroxisome proliferator-activated receptor gamma
affects expression
ISO
Gemcitabine affects the expression of PPARG mRNA
CTD
PMID:19427843
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
G
Ppfia4
PTPRF interacting protein alpha 4
increases expression
ISO
Gemcitabine results in increased expression of PPFIA4 mRNA
CTD
PMID:17039268
NCBI chr13:45,753,827...45,802,305
Ensembl chr13:45,753,827...45,802,261
G
Ppp1r15a
protein phosphatase 1, regulatory subunit 15A
increases expression
ISO
Gemcitabine results in increased expression of PPP1R15A mRNA
CTD
PMID:17039268
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
G
Psat1
phosphoserine aminotransferase 1
increases expression
ISO
Gemcitabine results in increased expression of PSAT1 mRNA
CTD
PMID:17039268
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
G
Ptch1
patched 1
affects expression
ISO
Gemcitabine affects the expression of PTCH1 mRNA
CTD
PMID:20103597
NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333
G
Pten
phosphatase and tensin homolog
affects expression
ISO
Gemcitabine affects the expression of PTEN mRNA
CTD
PMID:17039268
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
G
Ptgs1
prostaglandin-endoperoxide synthase 1
decreases expression
ISO
Gemcitabine results in decreased expression of PTGS1 mRNA
CTD
PMID:17039268
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
G
Ptgs2
prostaglandin-endoperoxide synthase 2
multiple interactions
ISO
[Curcumin co-treated with Gemcitabine] results in decreased expression of PTGS2 protein
CTD
PMID:17440100
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
G
Ptk2
protein tyrosine kinase 2
decreases response to substance
ISO
PTK2 protein results in decreased susceptibility to Gemcitabine
CTD
PMID:14623342
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
G
Ptpn11
protein tyrosine phosphatase, non-receptor type 11
affects expression
ISO
Gemcitabine affects the expression of PTPN11 mRNA
CTD
PMID:17039268
NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925
G
Rab8a
RAB8A, member RAS oncogene family
decreases expression
ISO
Gemcitabine results in decreased expression of RAB8A mRNA
CTD
PMID:17039268
NCBI chr16:17,654,027...17,675,385
Ensembl chr16:17,654,034...17,675,678
G
Rbm17
RNA binding motif protein 17
decreases response to substance
ISO
RBM17 protein results in decreased susceptibility to Gemcitabine
CTD
PMID:16061639
NCBI chr17:66,937,140...66,954,034
Ensembl chr17:66,937,140...66,954,014
G
Reg3b
regenerating family member 3 beta
decreases expression
ISO
Gemcitabine results in decreased expression of REG3A mRNA
CTD
PMID:16570353
NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015
G
Rel
REL proto-oncogene, NF-kB subunit
multiple interactions decreases expression
ISO
sulforaphane promotes the reaction [Gemcitabine results in decreased expression of REL protein]
CTD
PMID:20940707
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
G
Rela
RELA proto-oncogene, NF-kB subunit
increases phosphorylation multiple interactions increases expression
ISO
Gemcitabine results in increased phosphorylation of RELA protein [Gemcitabine co-treated with Doxorubicin co-treated with Paclitaxel] affects the localization of RELA protein; [Gemcitabine co-treated with Doxorubicin co-treated with Paclitaxel] results in increased expression of RELA protein; licoricidin inhibits the reaction [Gemcitabine results in increased phosphorylation of RELA protein]; Mastic Resin inhibits the reaction [Gemcitabine results in increased expression of RELA protein] [Curcumin co-treated with Gemcitabine] results in decreased expression of RELA protein
CTD
PMID:17039268 PMID:17440100 PMID:20523344 PMID:29782821
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
G
Rgs2
regulator of G-protein signaling 2
increases expression
ISO
Gemcitabine results in increased expression of RGS2 mRNA
CTD
PMID:17039268
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
G
Rnf149
ring finger protein 149
increases expression
ISO
Gemcitabine results in increased expression of RNF149 mRNA
CTD
PMID:17039268
NCBI chr 9:41,826,825...41,854,381
Ensembl chr 9:41,830,233...41,854,279
G
Rpl37
ribosomal protein L37
increases expression
ISO
Gemcitabine results in increased expression of RPL37 mRNA
CTD
PMID:17039268
NCBI chr 2:54,215,352...54,217,429
Ensembl chr 2:54,215,469...54,217,442
G
Rragd
Ras-related GTP binding D
increases expression
ISO
Gemcitabine results in increased expression of RRAGD mRNA
CTD
PMID:17039268
NCBI chr 5:47,373,902...47,409,369
Ensembl chr 5:47,373,463...47,409,356
G
Rrm1
ribonucleotide reductase catalytic subunit M1
affects response to substance multiple interactions
ISO
RRM1 protein affects the susceptibility to Gemcitabine [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of RRM1 mRNA; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of RRM1 protein
CTD
PMID:25189999 PMID:26894857
NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261
G
Rrm2
ribonucleotide reductase regulatory subunit M2
decreases response to substance multiple interactions affects response to substance
ISO
RRM2 protein results in decreased susceptibility to Gemcitabine [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of RRM2 protein RRM2 protein affects the susceptibility to Gemcitabine
CTD
PMID:14661056 PMID:25189999 PMID:26894857
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
G
Rsl24d1
ribosomal L24 domain containing 1
increases expression
ISO
Gemcitabine results in increased expression of RSL24D1 mRNA
CTD
PMID:17039268
NCBI chr 8:73,852,991...73,861,996
Ensembl chr 8:73,852,996...73,862,001
G
Sat1
spermidine/spermine N1-acetyl transferase 1
increases expression
ISO
Gemcitabine results in increased expression of SAT1 mRNA
CTD
PMID:17039268
NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813
G
Scd
stearoyl-CoA desaturase
increases expression
ISO
Gemcitabine results in increased expression of SCD mRNA
CTD
PMID:17039268
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
G
Sfn
stratifin
affects response to substance decreases response to substance increases methylation multiple interactions
ISO
SFN protein affects the susceptibility to Gemcitabine SFN protein results in decreased susceptibility to Gemcitabine Gemcitabine results in increased methylation of SFN gene [DNMT1 protein binds to SFN promoter] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; [Gemcitabine results in decreased susceptibility to Gemcitabine] inhibits the reaction [DNMT1 protein binds to SFN promoter]; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in decreased methylation of SFN gene; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of SFN mRNA; [Gemcitabine results in decreased susceptibility to Gemcitabine] which results in increased expression of SFN protein; [UHRF1 protein promotes the reaction [DNMT1 protein binds to SFN promoter]] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; SFN protein affects the reaction [YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to Gemcitabine]]; SFN protein inhibits the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein]; SFN protein inhibits the reaction [Gemcitabine results in increased cleavage of PARP1 protein]; SFN protein promotes the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to Gemcitabine]
CTD
PMID:25189999 PMID:26894857
Ensembl chr 5:145,826,201...145,831,314
G
Shh
sonic hedgehog signaling molecule
decreases expression
ISO
Gemcitabine results in decreased expression of SHH mRNA
CTD
PMID:20103597
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
G
Slc25a29
solute carrier family 25 member 29
increases expression
ISO
Gemcitabine results in increased expression of SLC25A29 mRNA
CTD
PMID:17039268
NCBI chr 6:127,742,027...127,752,915
Ensembl chr 6:127,742,033...127,752,940
G
Slc28a1
solute carrier family 28 member 1
multiple interactions
EXP ISO
Gemcitabine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] Gemcitabine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine]
CTD
PMID:8713072 PMID:10772724
NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
G
Slc29a1
solute carrier family 29 member 1
affects response to substance increases response to substance decreases response to substance multiple interactions increases uptake
ISO
SLC29A1 protein affects the susceptibility to Gemcitabine SLC29A1 mRNA results in increased susceptibility to Gemcitabine; SLC29A1 protein results in increased susceptibility to Gemcitabine SLC29A1 protein results in decreased susceptibility to Gemcitabine 4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein results in increased uptake of Gemcitabine]; [S 1 (combination) results in increased expression of SLC29A1 mRNA] which results in increased uptake of Gemcitabine; Fluorouracil promotes the reaction [SLC29A1 protein results in increased uptake of Gemcitabine]
CTD
PMID:15501974 PMID:16868479 PMID:17695509 PMID:18383843 PMID:18452103 PMID:18490900 PMID:18728667 PMID:18992248 PMID:26894857 More...
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
G
Slc29a3
solute carrier family 29 member 3
affects transport
ISO
SLC29A3 protein affects the transport of Gemcitabine
CTD
PMID:19164483
NCBI chr20:28,645,265...28,685,388
Ensembl chr20:28,647,391...28,685,388
G
Slc2a3
solute carrier family 2 member 3
increases expression
ISO
Gemcitabine results in increased expression of SLC2A3 mRNA
CTD
PMID:17039268
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
G
Slc43a3
solute carrier family 43, member 3
decreases expression
ISO
Gemcitabine results in decreased expression of SLC43A3 mRNA
CTD
PMID:17039268
NCBI chr 3:70,008,160...70,030,324
Ensembl chr 3:70,009,313...70,029,749
G
Slitrk2
SLIT and NTRK-like family, member 2
increases expression
ISO
Gemcitabine results in increased expression of SLITRK2 mRNA
CTD
PMID:17039268
NCBI chr X:145,246,448...145,259,983
Ensembl chr X:145,246,460...145,271,220
G
Smg1
SMG1, nonsense mediated mRNA decay associated PI3K related kinase
decreases response to substance multiple interactions
ISO
SMG1 protein results in decreased susceptibility to Gemcitabine SMG1 protein inhibits the reaction [Gemcitabine results in increased activity of CASP3 protein]; SMG1 protein inhibits the reaction [Gemcitabine results in increased activity of CASP9 protein]
CTD
PMID:21418860
NCBI chr 1:172,441,892...172,543,667
Ensembl chr 1:172,444,936...172,543,698
G
Smo
smoothened, frizzled class receptor
increases expression
ISO
Gemcitabine results in increased expression of SMO mRNA
CTD
PMID:25605917
NCBI chr 4:58,344,101...58,372,828
Ensembl chr 4:58,343,529...58,373,829
G
Sox2
SRY-box transcription factor 2
increases expression
ISO
Gemcitabine results in increased expression of SOX2 mRNA
CTD
PMID:25605917
NCBI chr 2:117,536,929...117,539,338
Ensembl chr 2:117,536,929...117,539,338
G
Spp1
secreted phosphoprotein 1
increases expression
ISO
Gemcitabine results in increased expression of SPP1 mRNA
CTD
PMID:17039268
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
G
Src
SRC proto-oncogene, non-receptor tyrosine kinase
affects response to substance multiple interactions decreases response to substance
ISO
SRC protein affects the susceptibility to Gemcitabine [AG 1879 co-treated with SRC] results in increased susceptibility to Gemcitabine SRC protein modified form results in decreased susceptibility to Gemcitabine; SRC protein results in decreased susceptibility to Gemcitabine
CTD
PMID:15073106 PMID:15194078
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
G
Stat3
signal transducer and activator of transcription 3
decreases activity
ISO
Gemcitabine results in decreased activity of STAT3 protein
CTD
PMID:22348037
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
G
Syncrip
synaptotagmin binding, cytoplasmic RNA interacting protein
decreases expression
ISO
Gemcitabine results in decreased expression of SYNCRIP mRNA
CTD
PMID:17039268
NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515
G
Szrd1
SUZ RNA binding domain containing 1
decreases expression
ISO
Gemcitabine results in decreased expression of SZRD1 mRNA
CTD
PMID:17039268
NCBI chr 5:153,418,748...153,443,286
Ensembl chr 5:153,418,748...153,443,252
G
Tceal9
transcription elongation factor A like 9
increases expression
ISO
Gemcitabine results in increased expression of TCEAL9 mRNA
CTD
PMID:17039268
NCBI chr X:99,245,645...99,247,715
Ensembl chr X:99,228,458...99,247,763
G
Tcof1
treacle ribosome biogenesis factor 1
decreases expression
ISO
Gemcitabine results in decreased expression of TCOF1 mRNA
CTD
PMID:17039268
NCBI chr18:54,267,015...54,300,324
Ensembl chr18:54,267,026...54,300,324
G
Tert
telomerase reverse transcriptase
multiple interactions decreases activity
ISO
[Fluorouracil co-treated with Gemcitabine] results in decreased activity of TERT protein Gemcitabine results in decreased activity of TERT protein
CTD
PMID:16929163
NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
G
Tfap2a
transcription factor AP-2 alpha
increases response to substance multiple interactions
ISO
TFAP2A protein results in increased susceptibility to Gemcitabine [TFAP2A protein co-treated with TP53 gene mutant form] results in decreased susceptibility to Gemcitabine
CTD
PMID:21489314
NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
G
Tgfb1
transforming growth factor, beta 1
multiple interactions decreases response to substance
ISO
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; U 0126 inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]
CTD
PMID:21613822
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
G
Tgfb2
transforming growth factor, beta 2
increases expression
ISO
Gemcitabine results in increased expression of TGFB2 mRNA
CTD
PMID:17039268
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
G
Thpo
thrombopoietin
increases expression
ISO
Gemcitabine results in increased expression of THPO protein
CTD
PMID:20531411
Ensembl chr11:80,182,820...80,188,167
G
Tnf
tumor necrosis factor
increases expression affects expression
ISO
Gemcitabine results in increased expression of TNF protein Gemcitabine affects the expression of TNF mRNA
CTD
PMID:17039268 PMID:20531411
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Tnfaip3
TNF alpha induced protein 3
increases expression
ISO
Gemcitabine results in increased expression of TNFAIP3 mRNA
CTD
PMID:17039268
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
G
Tnfrsf11b
TNF receptor superfamily member 11B
increases expression
ISO
Gemcitabine results in increased expression of TNFRSF11B mRNA
CTD
PMID:17039268
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
G
Tnfsf10
TNF superfamily member 10
multiple interactions
ISO
[TNFSF10 co-treated with Gemcitabine] affects the localization of BAX protein; [TNFSF10 co-treated with Gemcitabine] results in increased activity of CASP8 protein
CTD
PMID:17671697
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
G
Tnfsf8
TNF superfamily member 8
multiple interactions
ISO
[Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of TNFSF8 protein
CTD
PMID:24979617
NCBI chr 5:77,253,881...77,277,078
Ensembl chr 5:77,251,373...77,277,421
G
Tp53
tumor protein p53
increases expression affects activity multiple interactions
ISO
Gemcitabine results in increased expression of TP53 protein Gemcitabine affects the activity of TP53 protein [TFAP2A protein co-treated with TP53 gene mutant form] results in decreased susceptibility to Gemcitabine; Nicotine inhibits the reaction [Gemcitabine results in increased expression of TP53 protein]
CTD
PMID:12082016 PMID:16601104 PMID:17671697 PMID:21489314 PMID:35435491
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Tp53bp1
tumor protein p53 binding protein 1
increases expression
ISO
Gemcitabine results in increased expression of TP53BP1 mRNA
CTD
PMID:17039268
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
G
Tp53inp1
tumor protein p53 inducible nuclear protein 1
increases expression
ISO
Gemcitabine results in increased expression of TP53INP1 mRNA
CTD
PMID:16570353 PMID:17039268
NCBI chr 5:24,253,986...24,272,250
Ensembl chr 5:24,260,568...24,267,968
G
Traf1
TNF receptor-associated factor 1
affects expression
ISO
Gemcitabine affects the expression of TRAF1 mRNA
CTD
PMID:17039268
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
G
Tube1
tubulin, epsilon 1
increases expression
ISO
Gemcitabine results in increased expression of TUBE1 mRNA
CTD
PMID:17039268
NCBI chr20:42,552,362...42,570,648
Ensembl chr20:42,552,437...42,570,314
G
Tymp
thymidine phosphorylase
affects response to substance multiple interactions
ISO
TYMP protein affects the susceptibility to Gemcitabine [TYMP protein co-treated with DPYD protein] affects the susceptibility to Gemcitabine; TYMP protein affects the susceptibility to [Gemcitabine co-treated with Mitomycin]
CTD
PMID:18728667
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
G
Tyrp1
tyrosinase-related protein 1
affects expression
ISO
Gemcitabine affects the expression of TYRP1 mRNA
CTD
PMID:17039268
NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
G
Ube2c
ubiquitin-conjugating enzyme E2C
decreases expression
ISO
Gemcitabine results in decreased expression of UBE2C mRNA
CTD
PMID:17039268
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
G
Uggt2
UDP-glucose glycoprotein glucosyltransferase 2
increases expression
ISO
Gemcitabine results in increased expression of UGGT2 mRNA
CTD
PMID:17039268
NCBI chr15:96,074,557...96,239,365
Ensembl chr15:96,074,564...96,237,806
G
Uhrf1
ubiquitin-like with PHD and ring finger domains 1
multiple interactions
ISO
[Gemcitabine results in decreased susceptibility to Gemcitabine] which results in decreased expression of UHRF1 protein; [UHRF1 protein promotes the reaction [DNMT1 protein binds to SFN promoter]] inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]; UHRF1 protein inhibits the reaction [Gemcitabine results in decreased susceptibility to Gemcitabine]
CTD
PMID:25189999
NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631
G
Vcam1
vascular cell adhesion molecule 1
decreases expression
ISO
Gemcitabine results in decreased expression of VCAM1 protein
CTD
PMID:20531411
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
G
Vegfa
vascular endothelial growth factor A
increases expression multiple interactions
ISO
Gemcitabine results in increased expression of VEGFA mRNA [Curcumin co-treated with Gemcitabine] results in decreased expression of VEGFA protein
CTD
PMID:17039268 PMID:17440100
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
G
Vgf
VGF nerve growth factor inducible
decreases expression
ISO
Gemcitabine results in decreased expression of VGF mRNA
CTD
PMID:17039268
NCBI chr12:19,637,313...19,645,123
Ensembl chr12:19,637,320...19,640,341
G
Vldlr
very low density lipoprotein receptor
increases expression
ISO
Gemcitabine results in increased expression of VLDLR mRNA
CTD
PMID:17039268
NCBI chr 1:224,813,539...224,850,400
Ensembl chr 1:224,814,377...224,845,920
G
Vmp1
vacuole membrane protein 1
increases expression
ISO
Gemcitabine results in increased expression of VMP1
CTD
PMID:20299819
NCBI chr10:71,405,058...71,505,045
Ensembl chr10:71,405,452...71,505,007
G
Vwf
von Willebrand factor
decreases expression
ISO
Gemcitabine results in decreased expression of VWF protein
CTD
PMID:20531411
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
G
Wnt5a
Wnt family member 5A
decreases expression
ISO
Gemcitabine results in decreased expression of WNT5A mRNA
CTD
PMID:17039268
NCBI chr16:3,695,667...3,718,234
Ensembl chr16:3,697,032...3,718,234
G
Xbp1
X-box binding protein 1
multiple interactions
ISO
Gemcitabine promotes the reaction [1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-(2-(mopholin-4-yl)ethyl)-1H-indole results in increased expression of XBP1 mRNA]; Gemcitabine promotes the reaction [arachidonylcyclopropylamide results in increased expression of XBP1 mRNA]; Gemcitabine promotes the reaction [Rimonabant results in increased expression of XBP1 mRNA]
CTD
PMID:21525939
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
G
Xiap
X-linked inhibitor of apoptosis
affects response to substance
ISO
XIAP affects the susceptibility to Gemcitabine
CTD
PMID:16628085
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
G
Yap1
Yes1 associated transcriptional regulator
multiple interactions affects response to substance
ISO
SFN protein affects the reaction [YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to Gemcitabine]]; YAP1 protein affects the reaction [Gemcitabine results in increased activity of and results in increased cleavage of CASP8 protein]; YAP1 protein affects the reaction [Gemcitabine results in increased cleavage of PARP1 protein]; YAP1 protein promotes the reaction [SFN protein results in decreased susceptibility to Gemcitabine] YAP1 protein affects the susceptibility to Gemcitabine
CTD
PMID:26894857
NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010
G
Zfp110
zinc finger protein 110
increases expression
ISO
Gemcitabine results in increased expression of ZNF274 mRNA
CTD
PMID:17039268
NCBI chr 1:73,445,303...73,461,112
Ensembl chr 1:73,445,336...73,461,086
G
Zfp449
zinc finger protein 449
increases expression
ISO
Gemcitabine results in increased expression of ZNF449 mRNA
CTD
PMID:17039268
NCBI chr X:134,120,820...134,140,921
Ensembl chr X:134,122,636...134,140,924
G
Zfp521
zinc finger protein 521
decreases expression
ISO
Gemcitabine results in decreased expression of ZNF521 mRNA
CTD
PMID:17039268
NCBI chr18:4,775,952...5,068,592
Ensembl chr18:4,787,295...5,068,458
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all